|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
|
|---|---|---|---|---|---|---|---|
| Cash | |||||||
| Cash and cash equivalents | |||||||
| Due from Sponsor | |||||||
| Prepaid insurance current | |||||||
| Total current assets | |||||||
| Deferred offering costs associated with proposed public offering | |||||||
| Investments in Trust Account | |||||||
| Prepaid insurance | |||||||
| Total Assets | |||||||
| Accrued offering expenses | |||||||
| Accounts payable and accrued expenses | |||||||
| Due to related party | |||||||
| Due to sponsor | |||||||
| Total current liabilities | |||||||
| Deferred underwriting commission | |||||||
| Total liabilities | |||||||
| Commitments and Contingencies | |||||||
| Class A ordinary shares subject to possible redemption, 27,600,000 and 27,600,000 shares issued and outstanding at redemption value of $10.63 and $10.35 per share as of September 30, 2026, and December 31, 2025, respectively | |||||||
| Shareholders’ Deficit | |||||||
| Ordinary shares, value issued | |||||||
| Additional paid-in capital | |||||||
| Accumulated deficit | |||||||
| Total shareholders’ deficit | |||||||
| Total Liabilities and Shareholders’ Deficit |
Loading...